Curagen Corporation

Elma Fernandes

Richard August Shimkets

Henri Lichenstein

Meijia Yang

Ferenc L Boldog

Catherine Burgess

Michael Jeffers

John L Herrmann

Sudhirdas K Prayaga

William LaRochelle

Muralidhara Padigaru

Linda L Gorman

William Grosse

Denise M Lepley

Carol E A Pena

John P Alsobrook, Ii

Daniel K Rieger

Mei Zhong

The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.

Polypeptides of FGF-CX

The present invention provides FGF-CX polypeptides and polynucleotides, and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods of use for the FGF-CX polypeptide, polynucleotide and antibody.

Fibroblast growth factor and nucleic acids encoding same

This application is drawn to novel nucleic acid sequences encoding mammalian polypeptides that have sequence similarity to human angiopoietin-related proteins. The nucleic acid sequence is 1855 nucleotides long and contains an open reading frame from nucleotides 154-6 to 1369-71. The encoded polypeptides are about 405 amino acid residues in length.

Nucleic acid sequences encoding human angiopoietin-like polypeptides

Growing community of inventors

Branford, CT, United States of America

Elma Fernandes